Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SAVOIR trial

Toni Choueiri discusses how the phase 3 SAVOIR trial of savolitinib in MET-driven papillary renal cell carcinoma could inform future research despite being terminated early (4:23).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

13-07-2017 | Renal cell carcinoma | News

Savolitinib has potential in MET-driven papillary RCC

21-02-2020 | ASCO GU 2020 | Conference coverage | News

Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

21-02-2019 | Renal cell carcinoma | News

Immunotherapy-based regimens show promise in non-clear-cell RCC

05-03-2019 | Renal cell carcinoma | News

Cabozantinib efficacy extends to non-clear-cell RCC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits